Preparation method of novel genetically recombinant pure protein antigen

Abstract

The invention discloses a preparation method of a novel genetically recombinant pure protein antigen and relates to the technical field of protection of hemagglutinin viruses and development of detection reagents. The preparation process comprises the following steps: I, gene recombinant expression of a hemagglutinin H7 antigen; II, preparation of the hemagglutinin H7 antigen; III, application of the hemagglutinin pure protein to animals / human bodies; and IV, application of the high purity hemagglutinin H7 antigen to detecting hemagglutinin H7-containing viruses. The novel genetically recombinant pure protein antigen has the characteristics of high purity and good antigenicity, and does not exist in form of granules and not only does not contain any genetic materials such as RNA (Ribonucleic Acid), but also does not contain other protein impurities. The novel genetically recombinant pure protein antigen can be used for preparing a high specific antibody for H7N9. Because of the protein characteristic of the H7 antigen, the chromatographic method can be used for purifying a single antigen, and the purity of SEC-HPCL (Size Exclusion Chromatography-High Performance Liquid Chromatography) is higher than 90%. The high purity H7 antigen and the highly specific H7N9 antibody can be used for developing diagnostic reagents for diagnosing H7N9 avian influenza.

Description

Technical field [0001] The invention relates to the technical field of hemagglutinin virus protection and the development of detection reagents, in particular to a preparation process of a novel gene recombination pure protein antigen. Background technique [0002] H7N9 avian influenza is a new type of avian influenza, which was first discovered in Shanghai and Anhui at the end of March 2013. H7N9 avian influenza is the first new subtype of influenza virus discovered in the world. It has not yet been included in my country's legally reported infectious disease monitoring and reporting system, and no vaccine has been launched as of early April 2013. All patients infected by the virus have symptoms such as fever in the early stage. As of April 2013, it has not been confirmed whether the virus has the characteristics of human-to-human transmission. According to the investigation in April 2013, the H7N9 avian influenza virus gene was derived from genetic rematches between wild bird...

AI Technical Summary

Problems solved by technology

H7N9 avian influenza has caused a large number of infection cases in East China and other regions. At present, there is no effective prevention and treatment method. The H7N9 vaccines under research include inactivated and attenuated H7N9 viruses, genetically recombined H7N9 virus-like particles, etc. These Viruses and virus particles contain impurities such as neuraminidase, matrix protein, envelope, nucleoprotein, and RNA, which are not of high purity and cannot inhibit the spread of the virus